CoChat

Deconvolving Clinically Relevant Cellular Immune Cross-talk from Bulk Gene Expression Using CODEFACS and LIRICS Stratifies Patients with Melanoma to Anti–PD-1 Therapy

Open access
Wang, Kun, Patkar, Sushant, Lee, Joo Sang, Gertz, E. Michael, Robinson, Welles, Schischlik, Fiorella, Crawford, David R., Schäffer, Alejandro A., Ruppin, Eytan · 2022 · Cancer Discovery

Published version of a preprint

Cited by 55

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Abstract

The tumor microenvironment (TME) is a complex mixture of cell types whose interactions affect tumor growth and clinical outcome. To discover such interactions, we developed CODEFACS (COnfident DEconvolution For All Cell Subsets), a tool deconvolving cell type–specific gene expression in each sample from bulk expression, and LIRICS (Ligand–Receptor Interactions between Cell Subsets), a statistical framework prioritizing clinically relevant ligand–receptor interactions between cell types from the deconvolved data. We first demonstrate the superiority of CODEFACS versus the state-of-the-art deconvolution method CIBERSORTx. Second, analyzing The Cancer Genome Atlas, we uncover cell type–specific ligand–receptor interactions uniquely associated with mismatch-repair deficiency across different cancer types, providing additional insights into their enhanced sensitivity to anti–programmed cell death protein 1 (PD-1) therapy compared with other tumors with high neoantigen burden. Finally, we identify a subset of cell type–specific ligand–receptor interactions in the melanoma TME that stratify survival of patients receiving anti–PD-1 therapy better than some recently published bulk transcriptomics-based methods. Significance: This work presents two new computational methods that can deconvolve a large collection of bulk tumor gene expression profiles into their respective cell type–specific gene expression profiles and identify cell type–specific ligand–receptor interactions predictive of response to immune-checkpoint blockade therapy. This article is highlighted in the In This Issue feature, p. 873

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-21-0887

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Research works printed but not linked: 63

  1. Paget, 1889, The distribution of secondary growths in cancer of the breast, Lancet, 133, 571, 10.1016/S0140-6736(00)49915-0 · DOI · Paper page
  2. Ahn, 2013, DeMix: deconvolution for mixed cancer transcriptomes using raw measured data, Bioinformatics, 29, 1865, 10.1093/bioinformatics/btt301 · DOI
  3. Quon, 2013, Computational purification of individual tumor gene expression profiles leads to significant improvements in prognostic prediction, Genome Med, 5, 29, 10.1186/gm433 · DOI
  4. Fox, 2019, Landscape of transcriptomic interactions between breast cancer and its microenvironment, Nat Commun, 10, 3116, 10.1038/s41467-019-10929-z · DOI
  5. Newman, 2019, Determining cell type abundance and expression from bulk tissues with digital cytometry, Nat Biotechnol, 37, 773, 10.1038/s41587-019-0114-2 · DOI · Paper page
  6. Neftel, 2019, An integrative model of cellular states, plasticity, and genetics for glioblastoma, Cell, 178, 835, 10.1016/j.cell.2019.06.024 · DOI · Paper page
  7. Gentles, 2020, A human lung tumor microenvironment interactome identifies clinically relevant cell-type cross-talk, Genome Biol, 21, 107, 10.1186/s13059-020-02019-x · DOI
  8. Yu, 2012, clusterProfiler: an R package for comparing biological themes among gene clusters, OMICS, 16, 284, 10.1089/omi.2011.0118 · DOI · Paper page
  9. Carter, 2012, Absolute quantification of somatic DNA alterations in human cancer, Nat Biotechnol, 30, 413, 10.1038/nbt.2203 · DOI · Paper page
  10. Aran, 2015, Systematic pan-cancer analysis of tumour purity, Nat Commun, 6, 8971, 10.1038/ncomms9971 · DOI · Paper page
  11. Taylor, 2018, Genomic and functional approaches to understanding cancer aneuploidy, Cancer Cell, 33, 676, 10.1016/j.ccell.2018.03.007 · DOI · Paper page
  12. Loeb, 1991, Mutator phenotype may be required for multistage carcinogenesis, Cancer Res, 51, 3075
  13. Alexandrov, 2013, Signatures of mutational processes in human cancer, Nature, 500, 415, 10.1038/nature12477 · DOI · Paper page
  14. Muzny, 2012, Comprehensive molecular characterization of human colon and rectal cancer, Nature, 487, 330, 10.1038/nature11252 · DOI · Paper page
  15. Funkhouser, 2012, Relevance, pathogenesis, and testing algorithm for mismatch repair-defective colorectal carcinomas a report of the association for molecular pathology, J Mol Diagn, 14, 91, 10.1016/j.jmoldx.2011.11.001 · DOI · Paper page
  16. Cortes-Ciriano, 2017, A molecular portrait of microsatellite instability across multiple cancers, Nat Commun, 8, 15180, 10.1038/ncomms15180 · DOI · Paper page
  17. Galon, 2006, Type, density, and location of immune cells within human colorectal tumors predict clinical outcome, Science, 313, 1960, 10.1126/science.1129139 · DOI · Paper page
  18. Le, 2015, PD-1 blockade in tumors with mismatch-repair deficiency, New Engl J Med, 372, 2509, 10.1056/NEJMoa1500596 · DOI · Paper page
  19. Gurjao, 2020, Limited evidence of tumour mutational burden as a biomarker of response to immunotherapy, bioRxiv
  20. Robbins, 2013, Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells, Nat Med, 19, 747, 10.1038/nm.3161 · DOI · Paper page
  21. Kalaora, 2018, Combined analysis of antigen presentation and T-cell recognition reveals restricted immune responses in melanoma, Cancer Discov, 8, 1366, 10.1158/2159-8290.CD-17-1418 · DOI
  22. Bonneville, 2017, Landscape of microsatellite instability across 39 cancer types, JCO Precis Oncol, 1, PO.17.00073
  23. Litchfield, 2020, Escape from nonsense-mediated decay associates with anti-tumor immunogenicity, Nat Commun, 11, 3800, 10.1038/s41467-020-17526-5 · DOI
  24. McGrail, 2020, Proteome instability is a therapeutic vulnerability in mismatch repair-deficient cancer, Cancer Cell, 37, 371, 10.1016/j.ccell.2020.01.011 · DOI
  25. Rodvold, 2017, Intercellular transmission of the unfolded protein response promotes survival and drug resistance in cancer cells, Sci Signal, 10, eaah7177, 10.1126/scisignal.aah7177 · DOI
  26. Pelka, 2021, Spatially organized multicellular immune hubs in human colorectal cancer, Cell, 184, 4734, 10.1016/j.cell.2021.08.003 · DOI · Paper page
  27. Gros, 2014, PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors, J Clin Invest, 124, 2246, 10.1172/JCI73639 · DOI · Paper page
  28. Subbiah, 2020, The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) >= 10: a decision centered on empowering patients and their physicians, Ann Oncol, 31, 1115, 10.1016/j.annonc.2020.07.002 · DOI · Paper page
  29. Strickler, 2021, Tumor mutational burden as a predictor of immunotherapy response: is more always better?, Clin Cancer Res, 27, 1236, 10.1158/1078-0432.CCR-20-3054 · DOI · Paper page
  30. Cancer Genome Atlas Research Network, 2013, The Cancer Genome Atlas pan-cancer analysis project, Nat Genet, 45, 1113, 10.1038/ng.2764 · DOI · Paper page
  31. Auslander, 2018, Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma, Nat Med, 24, 1545, 10.1038/s41591-018-0157-9 · DOI · Paper page
  32. Davoli, 2017, Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy, Science, 355, eaaf8399, 10.1126/science.aaf8399 · DOI · Paper page
  33. Steiniche, 2019, T-cell–inflamed gene expression profile (GEP) and PD-L1 expression in patients (pts) with esophageal cancer (EC), J Clin Oncol, 37, 26, 10.1200/JCO.2019.37.4_suppl.26 · doi:10.1200/jco.2019.37.4_suppl.26
  34. Ock, 2017, Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers, Nat Commun, 8, 1050, 10.1038/s41467-017-01018-0 · DOI · Paper page
  35. Perez-Guijarro, 2020, Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy, Nat Med, 26, 781, 10.1038/s41591-020-0818-3 · DOI · Paper page
  36. Billadeau, 2002, ITAMs versus ITIMs: striking a balance during cell regulation, J Clin Invest, 109, 161, 10.1172/JCI0214843 · DOI · Paper page
  37. Staub, 2004, Systematic identification of immunoreceptor tyrosine-based inhibitory motifs in the human proteome, Cell Signal, 16, 435, 10.1016/j.cellsig.2003.08.013 · DOI
  38. Varin, 2010, B-cell tolerance breakdown in Sjogren's syndrome: focus on BAFF, Autoimmun Rev, 9, 604, 10.1016/j.autrev.2010.05.006 · DOI
  39. Murphy, 2016, Janeway's immunobiology, 10.1201/9781315533247 · DOI · Paper page
  40. Campbell, 2011, Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations, Immunology, 132, 315, 10.1111/j.1365-2567.2010.03398.x · DOI · Paper page
  41. Pende, 2019, Killer Ig-like receptors (KIRs): their role in NK cell modulation and developments leading to their clinical exploitation, Front Immunol, 10, 1179, 10.3389/fimmu.2019.01179 · DOI · Paper page
  42. Gonçalves, 2018, CD6, a rheostat-type signalosome that tunes T cell activation, Front Immunol, 9, 2994, 10.3389/fimmu.2018.02994 · DOI
  43. Chen, 2014, The function of BAFF on T helper cells in autoimmunity, Cytokine Growth Factor Rev, 25, 301, 10.1016/j.cytogfr.2013.12.011 · DOI
  44. Chen, 2015, Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model, Cancer Immunol Res, 3, 149, 10.1158/2326-6066.CIR-14-0118 · DOI · Paper page
  45. Ma, 2019, A CD40 agonist and PD-1 antagonist antibody reprogram the microenvironment of nonimmunogenic tumors to allow T-cell-mediated anticancer activity, Cancer Immunol Res, 7, 428, 10.1158/2326-6066.CIR-18-0061 · DOI · Paper page
  46. Barber, 2014, Costimulation of effector CD8+ T cells: which receptor is optimal for immunotherapy?, MOJ Immunol, 1, 00011, 10.15406/moji.2014.01.00011 · DOI
  47. Melero, 2013, Agonist antibodies to TNFR molecules that costimulate T and NK cells, Clin Cancer Res, 19, 1044, 10.1158/1078-0432.CCR-12-2065 · DOI · Paper page
  48. Philipson, 2020, 4-1BB costimulation promotes CAR T cell survival through noncanonical NF-kappaB signaling, Sci Signal, 13, eaay8248, 10.1126/scisignal.aay8248 · DOI · Paper page
  49. Siu, 2017, Preliminary results of a phase I/IIa study of BMS-986156 (glucocorticoid-induced tumor necrosis factor receptor–related gene [GITR] agonist), alone and in combination with nivolumab in pts with advanced solid tumors, J Clin Oncol, 35, 104, 10.1200/JCO.2017.35.15_suppl.104 · DOI · Paper page
  50. Tolcher, 2017, Phase Ib study of utomilumab (PF-05082566), a 4-1BB/CD137 agonist, in combination with Pembrolizumab (MK-3475) in patients with advanced solid tumors, Clin Cancer Res, 23, 5349, 10.1158/1078-0432.CCR-17-1243 · DOI · Paper page
  51. Cohen, 2019, A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors, J Immunother Cancer, 7, 342, 10.1186/s40425-019-0815-6 · DOI
  52. Wu, 2018, Limitations of alignment-free tools in total RNA-seq quantification, BMC Genomics, 19, 510, 10.1186/s12864-018-4869-5 · DOI · Paper page
  53. Everaert, 2017, Benchmarking of RNA-sequencing analysis workflows using whole-transcriptome RT-qPCR expression data, Sci Rep, 7, 1559, 10.1038/s41598-017-01617-3 · DOI · Paper page
  54. Teng, 2016, A benchmark for RNA-seq quantification pipelines, Genome Biol, 17, 74, 10.1186/s13059-016-0940-1 · DOI · Paper page
  55. Robert, 2015, Errors in RNA-seq quantification affect genes of relevance to human disease, Genome Biol, 16, 177, 10.1186/s13059-015-0734-x · DOI · Paper page
  56. Chu, 2020, Bayesian inference of cell composition and gene expression reveals tumor-microenvironment interactions, bioRxiv
  57. Bray, 2016, Near-optimal probabilistic RNA-seq quantification, Nat Biotechnol, 34, 525, 10.1038/nbt.3519 · DOI · Paper page
  58. Harrow, 2012, GENCODE: the reference human genome annotation for The ENCODE Project, Genome Res, 22, 1760, 10.1101/gr.135350.111 · DOI · Paper page
  59. Robinson, 2010, edgeR: a Bioconductor package for differential expression analysis of digital gene expression data, Bioinformatics, 26, 139, 10.1093/bioinformatics/btp616 · DOI · Paper page
  60. Robinson, 2010, A scaling normalization method for differential expression analysis of RNA-seq data, Genome Biol, 11, R25, 10.1186/gb-2010-11-3-r25 · DOI · Paper page
  61. Ma, 2019, Tumor cell biodiversity drives microenvironmental reprogramming in liver cancer, Cancer Cell, 36, 418, 10.1016/j.ccell.2019.08.007 · DOI · Paper page
  62. Karaayvaz, 2018, Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq, Nat Commun, 9, 3588, 10.1038/s41467-018-06052-0 · DOI · Paper page
  63. Bird, 2002, DNA methylation patterns and epigenetic memory, Genes Dev, 16, 6, 10.1101/gad.947102 · DOI · Paper page

Cited by

See all 55

Metadata

Authors
Wang, K., Patkar, S., Lee, J. S., Gertz, E. M., Robinson, W., Schischlik, F., Crawford, D. R., Schäffer, A. A., & Ruppin, E.
Venue
Cancer Discovery
Published
2022-01-04
Volume
12
Issue
4
Pages
1088-1105
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W4206676821
Cited by
55
References
37
FWCI
3.31
Type
journal article
Language
en
Open access
hybrid
Funders
HHS | National Institutes of Health (1ZIABC011802-02)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Deconvolving Clinically Relevant Cellular Immune Cross-talk from Bulk Gene Expression Using CODEFACS and LIRICS Stratifies Patients with Melanoma to Anti–PD-1 Therapy. https://app.cochat.ai/papers/10.1158/2159-8290.cd-21-0887
The paper
Wang, K., Patkar, S., Lee, J. S., Gertz, E. M., Robinson, W., Schischlik, F., Crawford, D. R., Schäffer, A. A., & Ruppin, E. (2022). Deconvolving Clinically Relevant Cellular Immune Cross-talk from Bulk Gene Expression Using CODEFACS and LIRICS Stratifies Patients with Melanoma to Anti–PD-1 Therapy. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-21-0887

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.